Business
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the “LTIP”) for the Board of Directors, Corporate Ma
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hruCjDK29WWlg5.YGk148A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OQ--/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 7 / 2026","length":35,"tagName":"p"},{"type":"text","content":"Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026","length":137,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the “LTIP”) for the Board of Directors, Corporate Management and employees of Zealand Pharma, in accordance with the Company’s remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (the “Remuneration Policy”).","length":565,"tagName":"p"},{"type":"text","content":"Long-term incentive program","length":27,"tagName":"p"},{"type":"text","content":"Zealand Pharma has made the following awards under its long‑term incentive program, with the Company granting in total:","length":119,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"35,165 restricted share units ("RSUs") to Zealand Pharma's Board of Directors","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"175,106 performance share units ("PSUs") and 175,106 RSUs have been awarded to Zealand Pharma’s Corporate Management","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"73,017 RSUs have been awarded to Zealand Pharma's U.S. employees and","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"280,741 RSUs have been awarded to Zealand Pharma's employees in Denmark (except for members of Corporate Management).","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedLi...